DR. ALLAN MICHAEL WEISSMAN, M.D.
Osteopathic Medicine at Westfield Dr, Bethesda, MD
License number
Maryland D0045562
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
7512 Westfield Dr, Bethesda, MD 20817
Phone
(301) 229-1030
Personal information
See more information about ALLAN MICHAEL WEISSMAN at radaris.comName
Address
Phone
7512 Westfield Dr, Bethesda, MD 20817
Glen Echo, MD
7512 Westfield Dr, Bethesda, MD 20817
Professional information
See more information about ALLAN MICHAEL WEISSMAN at trustoria.com
Dr. Allan M Weissman, Bethesda MD - MD (Doctor of Medicine)
Dr. Allan M Weissman, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
7512 Westfield Dr, Bethesda 20817
(301) 229-1030 (Phone)
(301) 229-1030 (Phone)
Certifications:
Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1981
Barnes Hosp-Wash U Sch Med
Natl Inst Hlth
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1981
Barnes Hosp-Wash U Sch Med
Natl Inst Hlth
Ube2G2 Binding Domain In The Ubiquitin Ligase Gp78 And Methods Of Use Thereof
Ube2G2 Binding Domain In The Ubiquitin Ligase Gp78 And Methods Of Use Thereof
US Patent:
8420776, Apr 16, 2013
Filed:
Apr 27, 2005
Appl. No.:
11/597453
Inventors:
Allan Weissman - Bethesda MD, US
Jennifer Mariano - Frederick MD, US
Bo Chen - Frederick MD, US
Yien Che Tsai - Frederick MD, US
Jennifer Mariano - Frederick MD, US
Bo Chen - Frederick MD, US
Yien Che Tsai - Frederick MD, US
Assignee:
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
C07K 14/435, C12P 21/02
US Classification:
530326, 530324, 435 691
Abstract:
The present invention features isolated nucleic acid molecules, designated G2BD nucleic acid molecules, which encode the binding site from the gp78 ubiquitin ligase that binds to the Ube2G2 ubiquitin conjugating enzyme. The invention further provides isolated G2BD proteins and fusion proteins. Still further provided are diagnostic and therapeutic methods, as well as screening assays utilizing compositions of the invention.
Deazaflavin Compounds And Methods Of Use Thereof
Deazaflavin Compounds And Methods Of Use Thereof
US Patent:
2010004, Feb 25, 2010
Filed:
Feb 23, 2009
Appl. No.:
12/390692
Inventors:
Allan M. Weissman - Bethesda MD, US
Karen H. Vousden - Glasgow, GB
Jane P. Jensen - Potomac MD, US
Yili Yang - Montgomery Village MD, US
Shengyun Fang - Potomac MD, US
Douglas Woods - Auckland, NZ
John H. Kenten - Boyds MD, US
Ilia Davydov - North Potomac MD, US
Yassamin J. Safiran - Potomac MD, US
Pankaj Oberoi - Rockville MD, US
Karen H. Vousden - Glasgow, GB
Jane P. Jensen - Potomac MD, US
Yili Yang - Montgomery Village MD, US
Shengyun Fang - Potomac MD, US
Douglas Woods - Auckland, NZ
John H. Kenten - Boyds MD, US
Ilia Davydov - North Potomac MD, US
Yassamin J. Safiran - Potomac MD, US
Pankaj Oberoi - Rockville MD, US
Assignee:
Government of the US, as represented by the Secretary, Department of Health & Human Services - Rockville MD
BioVeris Corporation - Gaithersburg MD
BioVeris Corporation - Gaithersburg MD
International Classification:
A61K 31/519, C07D 239/70, A61P 35/00
US Classification:
514267, 544250
Abstract:
The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.
Inhibitors Of Ubiquitin E1
Inhibitors Of Ubiquitin E1
US Patent:
2012028, Nov 15, 2012
Filed:
Jul 12, 2012
Appl. No.:
13/547417
Inventors:
Allan M. Weissman - Bethesda MD, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Assignee:
The USA, as represented by the Secretary, Department of Health and Human Services - Bethesda MD
International Classification:
A61K 31/4155, A61P 31/18, A61P 31/12, A61P 35/00, A61P 35/02
US Classification:
514404
Abstract:
The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
Inhibitors Of Ubiquitin E1
Inhibitors Of Ubiquitin E1
US Patent:
2008030, Dec 11, 2008
Filed:
May 19, 2008
Appl. No.:
12/154156
Inventors:
Allan M. Weissman - Bethesda MD, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Assignee:
Government of the US, as represented by the Secretary, Department of Health and Human Services - Rockville MD
International Classification:
A61K 31/4152, C07D 231/04, C12N 5/00, A61P 31/12, A61P 37/02, A61P 29/00
US Classification:
514404, 5483657, 435375
Abstract:
The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
Inhibitors Of Ubiquitin E1
Inhibitors Of Ubiquitin E1
US Patent:
8242160, Aug 14, 2012
Filed:
Jul 23, 2010
Appl. No.:
12/842346
Inventors:
Allan M. Weissman - Bethesda MD, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Yili Yang - Montgomery Village MD, US
Jane P. Jensen - Gettysburg PA, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A61K 31/4152
US Classification:
514404
Abstract:
The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
Deazaflavin Compounds And Methods Of Use Thereof
Deazaflavin Compounds And Methods Of Use Thereof
US Patent:
2006021, Sep 21, 2006
Filed:
Feb 12, 2004
Appl. No.:
10/545547
Inventors:
Allan Weissman - Bethesda MD, US
Karen Vousden - Glasgow, GB
Jane Jensen - Potomac MD, US
Yili Yang - Montgomery Village MD, US
Shengyun Fang - Potomac MD, US
Douglas Woods - Gaithersburg MD, US
John Kenten - Boyds MD, US
Ilia Davydov - North Potomac MD, US
Yassamin Safiran - Potomac MD, US
Pankaj Oberoi - Rockville MD, US
Karen Vousden - Glasgow, GB
Jane Jensen - Potomac MD, US
Yili Yang - Montgomery Village MD, US
Shengyun Fang - Potomac MD, US
Douglas Woods - Gaithersburg MD, US
John Kenten - Boyds MD, US
Ilia Davydov - North Potomac MD, US
Yassamin Safiran - Potomac MD, US
Pankaj Oberoi - Rockville MD, US
Assignee:
GOVERNMENT OF THE US, AS REPRESENTED BY THE SEC- RETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES - ROCKEVILLE MD
BioVERIS CORPORATION - GAITHERSBURG MD
BioVERIS CORPORATION - GAITHERSBURG MD
International Classification:
A61K 31/519, C07D 487/02
US Classification:
514267000, 544250000
Abstract:
The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.
Highly Soluble Pyrimido-Dione-Quinoline Compounds And Their Use In The Treatment Of Cancer
Highly Soluble Pyrimido-Dione-Quinoline Compounds And Their Use In The Treatment Of Cancer
US Patent:
2010005, Mar 4, 2010
Filed:
Jun 13, 2007
Appl. No.:
12/304980
Inventors:
Allan Weissman - Bethesda MD, US
Yili Yang - Montgomery Village MD, US
Yili Yang - Montgomery Village MD, US
Assignee:
Government of the US, as represented by the Secretary, Dept. of Health and Human Services - Rockville MD
International Classification:
A61K 31/519, C07D 471/04, A61P 35/00
US Classification:
514267, 544250
Abstract:
The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.